# GenomeFrontier Therapeutics

Source: https://onco.cc/companies/genomefrontier-therapeutics/  
OnCo record `genomefrontier-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GenomeFrontier Therapeutics makes CAR T-cell therapies, in which a patient's own immune cells are engineered to attack cancer, using a method that does not need a virus to carry the new gene. Its first product targets two markers on B-cell lymphoma cells.

## Summary

GenomeFrontier Therapeutics, headquartered in Xizhi District, New Taipei City, Taiwan, develops CAR T and TCR T cell therapies with its Quantum Engine system, which combines four virus-free gene and cell engineering platforms including a piggyBac-based vector (Quantum pBac) and a delivery method it calls Quantum Nufect. Its lead product GF-CART01 is a dual-targeting CD20/CD19 CAR T with a safety switch, in a phase 1 3+3 dose-escalation study (NCT06703892) in relapsed or refractory B-cell haematological malignancies including diffuse large B-cell, follicular and primary mediastinal large B-cell lymphoma, at a site in Taipei. GF-CART02 targets multiple myeloma and GF-CART03 is an armoured multi-target CAR T for solid tumours. Its first registered cancer trial, NCT06703892, was posted on ClinicalTrials.gov in November 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: New Taipei City
- Type: cell-therapy
- Website: https://genomefrontier.com/

## Notes

- Founding year not stated on the pages read on 29 October 2026.
- The trial sponsor is GenomeFrontier Therapeutics TW Co., Ltd.; the website is that of GenomeFrontier Therapeutics, CORP.
- No financing round is recorded.

## Sources

- Official website: https://genomefrontier.com/
- Pipeline: https://genomefrontier.com/pipeline/
- ClinicalTrials.gov: phase 1 trial of GF-CART01 (NCT06703892): https://clinicaltrials.gov/study/NCT06703892

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Primary mediastinal (thymic) large B-cell lymphoma](https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)

---
JSON: https://onco.cc/api/v1/entities/genomefrontier-therapeutics.json